首页> 美国卫生研究院文献>other >Heterologous Erythromycin Production across Strain and Plasmid Construction
【2h】

Heterologous Erythromycin Production across Strain and Plasmid Construction

机译:跨菌株和质粒构建的异源红霉素生产

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The establishment of erythromycin production within the heterologous host E. coli marked an accomplishment in genetic transfer capacity. Namely, over 20 genes and 50 kb of DNA was introduced to E. coli for successful heterologous biosynthetic reconstitution. However, the prospect for production levels that approach those of the native host requires the application of engineering tools associated with E. coli. In this report, metabolic and genomic engineering were implemented to improve the E. coli cellular background and the plasmid platform supporting heterologous erythromycin formation. Results include improved plasmid stability and metabolic support for biosynthetic product formation. Specifically, the new plasmid design for erythromycin formation allowed for ≥89% stability relative to current standards (20% stability). In addition, the new strain (termed LF01) designed to improve carbon flow to the erythromycin biosynthetic pathway provided a 400% improvement in titer level.
机译:在异源宿主大肠杆菌中红霉素生产的建立标志着遗传转移能力的成就。即,将超过20个基因和50kb的DNA引入到大肠杆菌中以成功地进行异源生物合成重建。但是,要达到接近天然宿主的产量水平,就需要应用与大肠杆菌相关的工程工具。在本报告中,实施了代谢和基因组工程以改善大肠杆菌细胞本底和支持异源红霉素形成的质粒平台。结果包括改进的质粒稳定性和对生物合成产物形成的代谢支持。具体而言,用于红霉素形成的新质粒设计允许相对于当前标准品具有≥89%的稳定性(20%稳定性)。此外,新菌株(称为LF01)旨在提高流向红霉素生物合成途径的碳流量,使效价水平提高了400%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号